Keryx Biopharmaceuticals (NASDAQ: KERX) is an emerging small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex), under Special Protocol Assessment (SPA) agreements with the FDA. KERX is Aeterna Zentaris’ partner and licensee for perifosine in the USA, Canada and Mexico.
Bollinger Report recently introduced both KERX and AEZS for full coverage. Bollinger Report selected KERX for “its current position within the healthcare industry” and AEZS for “its changing role within the healthcare industry.”
Both reports can be downloaded for free at www.BollingerReport.com.